REG - Deltex Med Grp PLC - Director Dealing

Deltex MedicalAnnouncement

28/08/2018 07:05

RNS Number : 8879Y
Deltex Medical Group PLC
28 August 2018
 


28 August 2018
 
 
Deltex Medical Group plc
("Deltex Medical" or the "Company")
 
 
Director Dealing
 
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), was informed on Friday 24 August that Nigel Keen, Chairman of the Company, had that day purchased 2,000,000 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 0.9 pence per Ordinary Share.
 
Following these transactions, Mr Keen's beneficial ownership is 54,223,410 Ordinary Shares, representing approximately 11 per cent. of Deltex Medical's issued ordinary share capital.
 
For further information, please contact:-
 



Deltex Medical Group plc


01243 774 837
investorinfo@deltexmedical.com




Nigel Keen, Chairman








Andy Mears, Chief Executive 








Jonathan Shaw, Group Finance Director


















Nominated Adviser & Broker








Arden Partners plc
 


020 7614 5900




Chris Hardie
Ciaran Walsh


















Joint Broker








Turner Pope Investments (TPI) Ltd


0203 621 4120
info@turnerpope.com




Andy Thacker








 
Financial Public Relations








IFC Advisory
 


0203 934 6630




Tim Metcalfe
Graham Herring
Heather Armstrong












 
 
Notes for Editors
 
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM (TrueVueTM Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVueTM Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
 
Deltex Medical's TrueVueTM System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography (TrueVueTM Impedance) is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis

(TrueVueTM Pressurewave) uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
 
Group goal
 
Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.
 
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
 
Note: This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them.



  1
 


Details of the person discharging managerial responsibilities / person closely associated 




a)
 


Names 


Nigel Keen - Chairman




2
 


Reason for the notification




a)
 


Position/status
 


See 1(a) above for position - classified as a PDMR of Deltex Medical




b)
 


Initial notification /Amendment
 


Initial




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 




a)
 


Name
 


Deltex Medial Group plc
 




b)
 


LEI


213800XN34P6LI8J6M39




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 


Ordinary shares of 1 penny each ("Ordinary Shares")




b)


Identification code 
 


GB0059337583




c)
 


Nature of the transaction 
 


Purchase of Ordinary Shares
 




d)
 


Price(s) and volume(s)





Prices(s)


Volume(s)




0.9 pence


2,000,000








d)
 


Aggregated information 
- Aggregated volume
- Price








2,000,000



0.9 pence




e)
 


Date of the transaction 




24 August 2018




f)
 


Place of the transaction




London Stock Exchange, AIM Market (XLON)



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLIFITTVIDFIT